1. Davis MA. Epidemiology of osteoarthritis. Clin Geriatr Med 1988; 4: 241–55.
2. Pavelka K. Symptomatic treatment of osteoarthritis: paracetamol or NSAIDs? Int J Clin Pract 2004; 58 (Suppl. 144): 5–12.
3. Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. Osteoarthritis – an untreatable disease? Nat Rev Drug Discov 2005; 4: 331–44.
4. Bianchi M, Broggini M, Balzarini P et al. Влияние нимесулида на боль и концентрации в синовиальной жидкости субстанции Р, интерлейкина-6 и интерлейкина-8 у пациентов с остеоартритом коленного сустава. Сравнительное исследование с целекоксибом. Рус. мед. журн. Неврология. Психиатрия. 2010; 26.
5. Pincus T, Swearingen C, Cummins P, Callahan LF. Preference for nonsteroidal antiinflammatory drugs vs. acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. Rheumatol 2000; 27: 1020–7.
6. Wolfe F, Zhao S, Lane N. Preference for non-steroidal-anti-inflam-matory drugs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis and fibromyalgia. Arthritis Rheum 2000; 43: 378–85.
7. Лила А.М. Нимесулид в терапии болевого синдрома при остеоартрозе. Cons. Med. 2007; 8: 118–21.
8. Singla AK, Chawla M, Singh A. Nimesulid: some pharmaceutical and pharmacological aspects – an update. J Pharmac Pharmacol 2000; 52: 467–86.
9. Низовцева О.А. Применение нимесулида (селективного ингибитора ЦОГ-2) при остеоартрозе в сочетании с АГ. Трудный пациент. 2008; 11.
10. Bennet А, Villa G. Nimesulid: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Exp Opin Pharmacother 2000; 1: 277–86.
11. Насонов Е.Л. Перспективы применения нового нестероидного противовоспалительного препарата нимесулид. Клин. фармакология и терапия. 1999; 8: 65–9.
12. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. М.: ИМА-пресс, 2009.
13. Игнатов Ю.Д., Кукес В.Г., Мазуров В.И. Клиническая фармакология нестероидных противововспалительных средств. М.: ГЭОТАР-Медиа, 2010.
14. Famaey JP, Vandekerckhove K, Geczy J, Bruhwyler J. A large, open-label trial of nimesulide in patients with osteoarticular conditions treated in a general practice setting. Curr Ther Res Clin E 1998; 59 (7): 467–82.
15. Huskisson EC, Macciocchi A, Rahlfs VW et al. Nimesulide Versus Diclofenac in the Treatment of Osteoarthritis of the Hip or Knee: An Active Controlled Equivalence Study. Curr Ther Res Clin E 1999; 60 (5): 253–65.
16. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of Acute Low Back Pain with the COX-2-Selecti4'e Anti-Inflammatory Drug Nimesulide. Spine 2000; 25 (12): 1579–85.
17. Pelletier JP, Mineau F, Fernandes JC et al. Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts. Clin Exp Rheumatol 1997; 15: 393–8.
18. Mukherjee P, Rachita C, Aisen P, Pasinetti GM. Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol 2001; 19 (Suppl. 22): S7–11.
19. Dreiser RL. Nimesulidi in the treatment of osteoarthritis of the hip: A dose-finding study. Helsinn, Internal Report, 1991.
20. Bourgeois P, Dreiser RL, Lequesne MG et al. Multi-centre double-blind study to define the most favourable dose of Nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur J Rheum Inflam 1994; 14: 39–50.
21. Fossaluzza V, Montagnani G. Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double-blind trial versus naproxen. J Int Med Res 1989; 17 (3): 295–303.
22. Sarzi-Puttini P, Santadrea S, Boccassini L et al. The role of NSAID in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001; 19 (Suppl. 22): S17–20.
23. Барскова В.Г. Практическая ревматология. Нимесулид в терапевтической практике. Cons. Med. 2011; 13 (2).
24. European Medicines Agency, EMA. Patient Health Protection Assessment report for Nimesulide containing medicinal products for systemic use Pursuant to Article 31 of Directive 2001/83/EC, as amended International Non-proprietary Name: nimesulide Procedure number: EMEA/H/A-31/1261 Referral under Article 31 of Directive 2001/83/EC. 20 January 2012 EMA/73856/2012.
25. Бадалян О.Л., Бурд С.Г., Савенков А.А., Тертышник О.Ю. Особенности применения различных НПВП в клинической практике. Рус. мед. журн. Неврология. Психиатрия. 2009; 17 (20): 1298.
26. Drieser RL, Riebenfeld D. Nimesulide in the treatment of osteoarthritis. Drugs 1993; 46 (Suppl. 1): 1991–5.
27. Bianchi M, Broggini M. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide? Celecoxib and rofecocsib in osteoarthritis of the knee. Drugs 2003; 63 (Suppl. 1): 37–46.
28. Горячев Д.В., Балабанова Р.М. Нимесулид – начало эпохи селективных ингибиторов ЦОГ-2. Рус. мед. журн. Ревматология. 2003; 23.
29. De Groot J, Bank RA, Tchetverikov I et al. Molecular markers for osteoarthritis: the road ahead. Curr Opin Rheumatol 2002; 14 (5): 585–9.
30. Zivanović S, Rackov LP, Zivanović A et al. Cartilage oligomeric matrix protein-inflammation biomarker in knee osteoarthritis. Bosn J Basic Med Sci 2011; 11 (1): 27–32.
31. Pelletier JP, Martel-Pelletier J. Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs 1993; 46 (Suppl. 1): 34–9.
32. Barracchini A, Franceschini N, Amicosante G et al. Can non-steroidal anti-inflammatory drugs act as metalloproteinase modulators? An in-vitro study of inhibition of collagenase activity. J Pharm Pharmacol 1998; 50 (12): 1417–23.
33. Kullich WC, Niksic F, Klein G. Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: a pilot clinical study. Int J Clin Pract Suppl 2002; 128: 24–9.
34. Bevilacqua M, Devogelaer JP, Righini V et al. Effect of nimesulide on the serum levels of hyaluronan and stromelysin-1 in patients with osteoarthritis: a pilot study. Int J Clin Pract Suppl 2004; 144: 13―9.
35. Yang SF, Hsieh YS, Lue KH et al. Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans. Clin Biochem 2008; 41 (1–2): 109–16.
36. Савустьяненко А.В. Механизмы хондропротективного действия нимесулида. Боль. Суставы. Позвоночник. 2012; 1 (5).
37. Балабанова Р.М., Белов Б.С., Чичасова Н.В. и др. Эффективность нимесила при ревматоидном артрите. Клин. медицина. 2002; 80 (6): 49–52.
38. Барскова В.Г., Якунина И.А., Насонова В.А. Применение нимесила при подагрическом артрите. Терапевт. арх. 2003; 5: 60–4.
39. Барскова В.Г., Насонова В.А., Цапина Т.Н Эффективность и безопасность применения нимесила при подагрическом артрите. Клин. медицина. 2004; 82 (12): 49–54.
40. Bianchi M, Broggini M. Anti-hyperalgesic effects of nimesulide: studies in rats and humans. Int Clin Pract 2002; 57 (Suppl. 128): 11–9.
41. Vilensky JA, Cook JA. Neurogenic acceleration of osteoarthritis. Curr Opin Rheumatol 1998; 10: 251–5.
42. Saito T, Koshino T. Distribution of neuropeptides in synovium of the knee with osteoarthritis. Clin Orthop 2000; 376: 172–82.
43. Kean WF, Kean R, Buchanan WW. Osteoarthritis: symptoms, signs and source of pain. Inflammopharmacology 2004; 12: 3–31.
44. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999; 40: 1–11.
45. Pola E, Papaleo P, Pola R et al. Interleukin-6 gene polymorphism and risk of osteoarthritis of the hip: a case-control study. Osteoarthr Cartil 2005; 13: 1025–8.
46. Kaneko S, Satoh T, Chiba J et al. Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cell Mol Ther 2000; 6: 71–9.
47. Henrotin YE, Labasse AH, Simonis PE et al. Effects of nimesulide and sodium diclofenac on interleukin-6, interleukin-8, proteoglycans and prostaglandin E2 production by human articular chondrocytes in vitro. Clin Exp Rheumatol 1999; 17: 151–60.
48. Von Banchet GS, Kiehl M, Schaible HG. Acute and long-term effects of IL-6 on cultured dorsal root ganglion neurones from adult rat. Neurochem 2005; 94: 238–48.
49. Maffei Facino R, Carini M, Aldini G et al. Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide. Arzneimittelforschung 1995; 45: 1102–10.
50. Maffei-Facino R, Carini M, Aldini G. Anti-oxidant activity of nimesulide and its main metabolites. Drugs 1993; 46 (Suppl. 1): 15–21.
51. Bevilacqua M, Vago T, Baldi G et al. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacology 1994; 268: 415–23.
52. de Mello SB, Laurindo IM, Cossermelli W. Action of the 4-nitro-2-phenoximethanesulphonamide (nimesulide) on neutrophil chemotaxis and superoxide production. Sao Paulo Med J 1994; 112: 489–94.
53. Manicourt DH, Bevilacqua M, Righini V et al. Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-Telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. Drugs 2005; 6: 261–71.
54. Sandy JD. Proteolytic degradation of normal and osteoarthritic cartilage. In: Brandt KD, Doherty M, Lohmander LS (eds). Osteoarthritis, 2nd ed. Oxford: Oxford University Press, 2003; p. 82–92.
55. Clark IM, Murphy G. Matrix Proteinases. In: Seibel MJ, Robins SP, Bilezikian JP (eds). Dynamics of Bone and Cartilage Metabolism. San Diego: Academic Press, 1999; p. 137–50.
56. Cawston ТЕ. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther 1996; 3: 163–82.
57. Brew K, Dinarkarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267–83.
58. Dean DD, Martel-Pelletier J, Felletier JP et al. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989; 84: 678–85.
59. Kullich W, Fagerer N, Schwann H. Влияние нестероидного противовоспалительного препарата нимесулида на акцептор свободных радикалов глутатион-S-трансферазы у пациентов с остеоартритом коленного сустава. Рус. мед. журн. Ревматология. 2010; 11.
60. Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: An overview. Inflamm Res 1997; 46: 437–46.
61. Saito S, Katoh M, Masumoto M et al. Involvement of MMP-1 and MMP-3 in collagen degradation induced by IL-1 in rabbit cartilage explant culture. Life Sci 1998; 62: 359–65.
62. Wu JJ, Lark MW, Chun LE, Eyre DR. Sites of stromelysin cleavage in collagen types II, IX, and XI of cartilage. J Biol Chem 1991; 266: 5625–8.
63. Hui W, Rowan AD, Cawston T. Insulin-like growth factor 1 blocks collagen release and down regulates matrix metalloproteinase-1, -3, -8, and -13 mRNA expression in bovine nasal cartilage stimulated with oncostatin M in combination with interleukin 1a. Ann Rheum Dis 2001; 60: 254–61.
64. Billinghurst RC, Dahlberg L, lonescu M et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997; 99: 1534–45.
65. Kullich WC, Niksic F. Влияние нимесулида на уровни металлопротеиназ и деградацию матрикса при остеоартрите: поисковое клиническое исследование Clein G. Рус. мед. журн. Неврология. Психиатрия. 2010; 8.
66. Ottonello L, Uapino P, Scirocco MC et al. Sulfonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in inflammation? Clin Sci 1995; 88: 331–6.
67. Каратеев А.Е. Новые данные по безопасности НПВП: осложнений меньше, чем мы думали раньше. Cons. Med. Неврология/Ревматология (Прил.). 2010; 2: 48–55.

М.В.Журавлева1, Т.М.Черных2

1. ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РФ;
2. ГБОУ ВПО Воронежская государственная медицинская академия им. Н.Н.Бурденко Минздрава РФ